Combination therapy before surgery for stomach cancer
Part of Cancer clinical trials.
This trial tests a combination of radiation, chemotherapy (SOX), and two targeted drugs (apatinib and camrelizumab) before and after surgery for stomach or gastroesophageal junction cancer. It aims to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that has not spread to other organs (stage T3-4 N+ M0).
- You are healthy enough to have surgery after chemotherapy (ECOG score 0 or 1).
- Your organs (like liver, kidneys, bone marrow) are working well.
- If you are a man or woman able to have children, you agree to use effective birth control during and for 120 days after treatment.
- You are expected to live more than 12 months.
- You do not have high blood pressure that is not controlled, or bleeding problems, or a weak immune system (like HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This trial tests a combination of three treatments (fruquintinib, sintilimab, and SOX chemotherapy) given before and after surgery for stomach cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
Hear when a new Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.